JP Morgan Chase
FATE icon

JP Morgan Chase’s Fate Therapeutics FATE Stock Holding History

JP Morgan Chase’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.7K Buy
44,888
+1,452
+3% +$1.77K ﹤0.01% 6190
2025
Q4 		$42.7K Sell
43,436
-6,980
-14% -$8.38K ﹤0.01% 6289
2025
Q3 		$63.5K Sell
50,416
-8,158
-14% -$8.8K ﹤0.01% 6137
2025
Q2 		$65.6K Sell
58,574
-3,339,709
-98% -$3.88M ﹤0.01% 5798
2025
Q1 		$2.68M Buy
3,398,283
+1,728,721
+104% +$2.12M ﹤0.01% 3652
2024
Q4 		$2.75M Sell
1,669,562
-167,742
-9% -$423K ﹤0.01% 3907
2024
Q3 		$6.43M Buy
1,837,304
+283,080
+18% +$1.1M ﹤0.01% 3030
2024
Q2 		$5.1M Sell
1,554,224
-205,097
-12% -$898K ﹤0.01% 3020
2024
Q1 		$12.9M Sell
1,759,321
-313,185
-15% -$1.94M ﹤0.01% 2257
2023
Q4 		$7.75M Sell
2,072,506
-522,668
-20% -$1.23M ﹤0.01% 2708
2023
Q3 		$5.5M Sell
2,595,174
-133,469
-5% -$442K ﹤0.01% 2758
2023
Q2 		$13M Buy
2,728,643
+1,002,914
+58% +$5.54M ﹤0.01% 2062
2023
Q1 		$9.84M Buy
1,725,729
+258,725
+18% +$1.56M ﹤0.01% 2302
2022
Q4 		$14.8M Sell
1,467,004
-566,199
-28% -$10.6M ﹤0.01% 1900
2022
Q3 		$45.6M Buy
2,033,203
+35,796
+2% +$1.03M 0.01% 1084
2022
Q2 		$49.5M Buy
1,997,407
+135,701
+7% +$3.74M 0.01% 1041
2022
Q1 		$72.2M Sell
1,861,706
-70,758
-4% -$2.74M 0.01% 988
2021
Q4 		$113M Buy
1,932,464
+229,849
+13% +$13M 0.01% 829
2021
Q3 		$101M Buy
1,702,615
+131,052
+8% +$10.3M 0.01% 858
2021
Q2 		$136M Buy
1,571,563
+873,863
+125% +$70.4M 0.02% 763
2021
Q1 		$57.5M Buy
697,700
+97,698
+16% +$9.36M 0.01% 1098
2020
Q4 		$54.6M Buy
600,002
+5,947
+1% +$369K 0.01% 1028
2020
Q3 		$23.4M Buy
594,055
+65,978
+12% +$2.3M ﹤0.01% 1395
2020
Q2 		$18.1M Buy
528,077
+63,644
+14% +$1.9M ﹤0.01% 1432
2020
Q1 		$10.3M Buy
464,433
+137,613
+42% +$3.48M ﹤0.01% 1720
2019
Q4 		$6.39M Buy
326,820
+47,069
+17% +$747K ﹤0.01% 2494
2019
Q3 		$4.34M Buy
279,751
+5,357
+2% +$103K ﹤0.01% 2816
2019
Q2 		$5.61M Buy
274,394
+6,941
+3% +$125K ﹤0.01% 2539
2019
Q1 		$4.7M Sell
267,453
-192,440
-42% -$3.04M ﹤0.01% 2633
2018
Q4 		$5.9M Buy
459,893
+17,511
+4% +$244K ﹤0.01% 2439
2018
Q3 		$7.21M Sell
442,382
-8,859
-2% -$105K ﹤0.01% 2462
2018
Q2 		$5.12M Buy
451,241
+23,821
+6% +$262K ﹤0.01% 2666
2018
Q1 		$4.17M Buy
427,420
+398,372
+1,371% +$3.82M ﹤0.01% 2734
2017
Q4 		$177K Buy
29,048
+2,635
+10% +$11.8K ﹤0.01% 4465
2017
Q3 		$108K Buy
26,413
+5,403
+26% +$18.4K ﹤0.01% 4280
2017
Q2 		$68K Buy
21,010
+18,844
+870% +$72.2K ﹤0.01% 4282
2017
Q1 		$10K Buy
+2,166
New +$7.92K ﹤0.01% 4807
2016
Q4 		– Sell
-4,941
Closed -$15K – 5033
2016
Q3 		$15K Buy
+4,941
New +$12K ﹤0.01% 4241

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's FATE Position: Q1 2026 in Review

JP Morgan Chase increased its Fate Therapeutics (FATE) stake by 3.3% in Q1 2026, buying an estimated $1.77K and bringing the position to 44,888 shares worth $50.7K. The position accounts for ﹤0.01% of the portfolio, ranked #6190.

JP Morgan Chase first reported a position in FATE in Q3 2016 and has held it in 38 quarters since. The position peaked at $136M in Q2 2021. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • JP Morgan Chase held 44,888 shares of Fate Therapeutics worth $50.7K as of Q1 2026.
  • JP Morgan Chase bought 1,452 Fate Therapeutics shares in Q1 2026, an estimated $1.77K.
  • Fate Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6190 holding.
  • JP Morgan Chase first reported a position in Fate Therapeutics in Q3 2016 and has held it in 38 quarters since.
  • JP Morgan Chase's Fate Therapeutics position peaked at $136M in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.